EA200802159A1 - Введение агониста-антагониста пациентам с опиоидной зависимостью - Google Patents

Введение агониста-антагониста пациентам с опиоидной зависимостью

Info

Publication number
EA200802159A1
EA200802159A1 EA200802159A EA200802159A EA200802159A1 EA 200802159 A1 EA200802159 A1 EA 200802159A1 EA 200802159 A EA200802159 A EA 200802159A EA 200802159 A EA200802159 A EA 200802159A EA 200802159 A1 EA200802159 A1 EA 200802159A1
Authority
EA
Eurasian Patent Office
Prior art keywords
opioid
agonist
patient
antagonist
patients
Prior art date
Application number
EA200802159A
Other languages
English (en)
Inventor
Михаил Викторович Воронков
Ефим Давидович Нежинский
Левон Геворкович Исакульян
Дарья Александровна Очерет
Original Assignee
Михаил Викторович Воронков
Ефим Давидович Нежинский
Левон Геворкович Исакульян
Дарья Александровна Очерет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2006113790/14A external-priority patent/RU2006113790A/ru
Application filed by Михаил Викторович Воронков, Ефим Давидович Нежинский, Левон Геворкович Исакульян, Дарья Александровна Очерет filed Critical Михаил Викторович Воронков
Publication of EA200802159A1 publication Critical patent/EA200802159A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Способ уменьшения психологической опиоидной зависимости включает выбор пациента с аддикцией к опиоиду и введение пациенту опиоидного агониста-антагониста на протяжении по меньшей мере 14 дней, тем самым снижая влечение к опиоиду у пациента. Опиоидный агонист-антагонист вводят пациенту, который нуждается в среднем соблюдении протокола лечения по меньшей мере на 95%. Раскрыта также неинъекционная композиция, содержащая агонист-антагонист.
EA200802159A 2006-04-25 2007-04-20 Введение агониста-антагониста пациентам с опиоидной зависимостью EA200802159A1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
RU2006113790/14A RU2006113790A (ru) 2006-04-25 2006-04-25 Комбинация агонистов/антагонистов опиоидных рецепторов с антиретровирусными препаратами для повышения эффективности терапии вич-инфекции у лиц, страдающих опиоидной зависимостью
RU2006115061 2006-05-04
US82579906P 2006-09-15 2006-09-15
US82579206P 2006-09-15 2006-09-15
US82578506P 2006-09-15 2006-09-15
US89041207P 2007-02-16 2007-02-16
PCT/US2007/067101 WO2007127683A2 (en) 2006-04-25 2007-04-20 Administration of agonist-antagonist in opioid-dependent patients

Publications (1)

Publication Number Publication Date
EA200802159A1 true EA200802159A1 (ru) 2009-06-30

Family

ID=38656307

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802159A EA200802159A1 (ru) 2006-04-25 2007-04-20 Введение агониста-антагониста пациентам с опиоидной зависимостью

Country Status (4)

Country Link
US (1) US20090060871A1 (ru)
EP (1) EP2018178A4 (ru)
EA (1) EA200802159A1 (ru)
WO (1) WO2007127683A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
WO2012149113A1 (en) 2011-04-29 2012-11-01 University Of Medicine And Dentistry Of New Jersey Method of treating dyskinesia
US9918980B2 (en) * 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10736889B2 (en) * 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US5750534A (en) * 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6541515B2 (en) * 2000-08-09 2003-04-01 Merck & Co., Inc. HIV integrase inhibitors
WO2003053337A2 (en) * 2001-11-09 2003-07-03 Advanced Therapeutics & Diagnostics, Lc Therapeutic compositions
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects

Also Published As

Publication number Publication date
EP2018178A4 (en) 2009-12-16
WO2007127683A3 (en) 2008-10-30
US20090060871A1 (en) 2009-03-05
WO2007127683A2 (en) 2007-11-08
EP2018178A2 (en) 2009-01-28

Similar Documents

Publication Publication Date Title
HRP20191029T1 (hr) Derivati morfinana radi liječenja predoziranja lijekom
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
WO2006031856A3 (en) Biosynchronous transdermal drug delivery
JP2006501240A5 (ru)
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
BRPI0712976A2 (pt) uso de 2-aminotetralinas substituÍdas para a fabricaÇço de um medicamento para a prevenÇço, alÍvio e/ou tratamento de vÁrios tipos de dor
RS51688B (en) METHOTREXATE CONCENTRATED SOLUTIONS
KR102531366B1 (ko) 수면 장애의 치료 및 예방
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
DK1263729T3 (da) Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
MX2009009133A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.
EA200802159A1 (ru) Введение агониста-антагониста пациентам с опиоидной зависимостью
TNSN08506A1 (en) Substituted carboxamides